Initiating Coverage:Indegene - 24th September, 2026
We initiate coverage on Indegene with a BUY recommendation and a DCF-based target price of Rs 705/share, implying an upside of 18% from the CMP.
98 Views
Primer: Indegene (INDGN IN) - Aug 2026
Indegene is a specialized, digital-first service provider to the life sciences industry, capitalizing on the sector's growing need for...
96 Views
APAC Healthcare Weekly (April 26) – Sino Bio, Wuxi Bio, Astellas Pharma, Eisai, Celltrion, Cochlear
Sino Bio got fourth indication approval for Benmelstobart plus Anlotinib. Wuxi Biologics’ three facilities got Korean GMP certification. FDA...
351 Views
APAC Healthcare Weekly (January 25) – InSilico, Daiichi, Shionogi, Alteogen, HK Inno, Sun Pharma
InSilico entered outlicensing deal. Daiichi’s Enhertu got China approval for 6th indication. Shionogi will pick up Pfizer’s stake in ViiV...
529 Views
APAC Healthcare Weekly (September 14)–CSPC Pharm, TransThera, Samsung Bio, Daiichi Sankyo, Sun Pharm
CSPC Pharma’s NDA for Anbenitamab injection has been accepted in China. TransThera got trial approval for lead candidate. Samsung Bio signed $1.3B...
713 Views